© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 19, 1432,
October 2, 2002
© 2002 Oxford University Press
NEWS |
Correction
In a Sept. 4 News article ("A One-Two Punch: Light-Based Therapy Finds Tumors, Delivers Treatment," p. 1272), a number of details for an upcoming clinical trial were inaccurate. Paragraphs 12 and 13 of the article (pages 1273 and 1274) should have read as follows:The upcoming phase II trial will be performed at Mount Sinai Hospital in collaboration with Savio Woo, Ph.D., director of the Mount Sinai Institute for Gene Therapy and Molecular Medicine in New York. The researchers will test the combined power of gene therapy and molecular imaging in patients with either localized prostate cancer or colorectal cancer metastases in the liver. The researchers will treat the patients with an adenovirus that produces viral thymidine kinase (TK). In this case, the viral TK gene will not be under the control of a tissue-specific promoter, so the researchers will inject the virus containing the TK gene directly into the tumor bed.
The researchers will then administer a small dose of a radiolabeled probe that can detect viral TK, and they will image the tumor using PET. They then plan to administer larger therapeutic doses of ganciclovir to kill the cancer cells. Although the trial is not testing transcriptional targeting—those vectors are not yet approved for use in humans—the clinicians will have the benefit of seeing where TK is active and monitoring its activity over time.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||